India Healthcare: Revenue Compounds, Profit Re-Bases — Read The Mix, Not The Headline

A head-analyst view weaving Aurific same-store earnings data with Q3 FY2026 management commentary, ICRA/CRISIL/Pharmarack research and the FY27 policy stack to locate where the durable profit sits — and where this year's headline misleads.

Analyst memo

The sector is moving from a one-year profit surge to a normalised compounding base. FY2025 was exceptional — same-store PAT +45% on US generic windfalls and hospital one-offs — and FY2026p's -9% PAT is that base lapping, not demand failing. Revenue still compounds (+12% same-store, directional), margins remain rich (22.75% EBITDA, +1.6pp), and the edge sits in domestic formulations, the hospital build-out and specialty/CDMO optionality.

01 / View

Executive Summary

Indian healthcare is one of the steadier, more margin-rich macro sectors in our same-store panel, and FY2025 confirms it: same-store revenue grew +11%, EBITDA +20%, and the EBITDA margin rose to 22.75% (+1.6pp) — led by Pharmaceuticals & Biotechnology at 23.21% (+1.8pp). The constructive case is structural, not cyclical: resilient, price-led domestic formulations (IPM closed CY2025 at ~Rs 2.40 lakh crore on +8.1% value growth), a hospital build-out ICRA pegs at +18-20% revenue in FY27, and a widening specialty/biosimilar/CDMO mix. Directional FY2026 same-store revenue (+12% macro) sits squarely inside the external reads — ICRA/CRISIL's 7-9% sector and 9-11% for covered samples.

Members only

Continue reading with Aurific

The full note — snapshot, sector trends, evidence checklist, decision rules and watch list — is available to Aurific members. Sign in to keep reading, or request access.

AI-Generated Research Disclosure: This report or analysis was generated in whole or in part using non-deterministic artificial intelligence systems and may contain factual, analytical, calculation, attribution, summarisation, or omission errors. AI-generated content may not have been independently reviewed by a human. Verify all material information against cited primary sources before relying on it. This content is provided solely for general informational and research purposes and is not investment advice, a personalised recommendation, a recommendation to buy, sell, or hold any security, or an offer or solicitation. Aurific AI Private Limited is not registered with SEBI as an investment adviser or research analyst. The analysis does not consider your objectives, financial circumstances, risk tolerance, tax position, or suitability. Securities investments are subject to market risk; past performance, valuations, forecasts, and model estimates do not guarantee future results. Consult a SEBI-registered investment adviser before acting.